Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

he treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome ... on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, ... patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... , Multiporator / Electroporator 2510 , , , , , , ... , Protocol No. 4308 915.503 04/2002 ... , , , , , , , ... , , Cell type , ...
... , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.034 11/1999 , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
Cached Biology Technology:Azotobacter vinelandii 2Actinomyces viscosus 2A 20 2
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... National Centers for Coastal Ocean Science and the Monterey ... first remote detection of a harmful algal species and ... recently reported in the June issue of Oceanography ... NOAA,s effort to monitor the type and toxicity of ...
... National Institutes of Health has awarded a five year $20 ... for Clinical and Translational Science. The grant is the ... rich intellectual breadth of the UIC campus and adds to ... campus," said Paula Allen-Meares, UIC chancellor. Translational research -- ...
... nothing on Rice University biologist Amy Dunham. In a newly ... primatology,s long-standing mysteries: Why are male and female lemurs the ... to be much larger than females. Size is an advantage ... mating with them, and evolutionary biologists have long wondered why ...
Cached Biology News:Scientists report first remote, underwater detection of harmful algae, toxins 2$20 million NIH grant to transform clinical research at UIC 2New theory on why male, female lemurs same size 2New theory on why male, female lemurs same size 3
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... mini Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: